Cagrilintide 5mg + Sema 5mg
Cagrilintide 5mg + Sema 5mg
$ 170
Combines semaglutide, a GLP-1 receptor agonist approved (as Ozempic/Wegovy) for type 2 diabetes and chronic weight management, with cagrilintide, a long-acting amylin receptor agonist studied in clinical trials for additive weight loss when co-administered with GLP-1 therapy.
Benefits
✓ Superior weight loss (trials show ~25% body weight reduction)
✓ Synergistic appetite suppression via two distinct pathways
✓ Improved metabolic markers
✓ Better GI tolerability than escalating semaglutide dose alone
✓ Once-weekly injection convenience
✓ Synergistic appetite suppression via two distinct pathways
✓ Improved metabolic markers
✓ Better GI tolerability than escalating semaglutide dose alone
✓ Once-weekly injection convenience
Side Effects
• Nausea and vomiting
• Injection site reactions
• Decreased appetite (may become excessive)
• Constipation or diarrhea
• Fatigue
• Injection site reactions
• Decreased appetite (may become excessive)
• Constipation or diarrhea
• Fatigue
Half Life
Cagrilintide: ~7 days / Sema: ~7 days
Note
FOR LABORATORY / RESEARCH USE ONLY. Not for human use or consumption. Not for animal or veterinary use or testing. Not a drug, food, cosmetic, or medical device, and not evaluated or approved by the FDA. Compounded/blended combinations of these APIs are not FDA-approved products; the approved combination product (marketed abroad as Cagrisema) is only available through a licensed prescriber.
Cagrilintide 5mg + Sema 5mg
$ 170
Combines semaglutide, a GLP-1 receptor agonist approved (as Ozempic/Wegovy) for type 2 diabetes and chronic weight management, with cagrilintide, a long-acting amylin receptor agonist studied in clinical trials for additive weight loss when co-administered with GLP-1 therapy.
FOR LABORATORY / RESEARCH USE ONLY. Not for human use or consumption. Not for animal or veterinary use or testing. Not a drug, food, cosmetic, or medical device, and not evaluated or approved by the FDA. Compounded/blended combinations of these APIs are not FDA-approved products; the approved combination product (marketed abroad as Cagrisema) is only available through a licensed prescriber.
✓ Superior weight loss (trials show ~25% body weight reduction)
✓ Synergistic appetite suppression via two distinct pathways
✓ Improved metabolic markers
✓ Better GI tolerability than escalating semaglutide dose alone
✓ Once-weekly injection convenience
✓ Synergistic appetite suppression via two distinct pathways
✓ Improved metabolic markers
✓ Better GI tolerability than escalating semaglutide dose alone
✓ Once-weekly injection convenience
Cagrilintide: ~7 days / Sema: ~7 days
